Ayala Pharmaceuticals Inc (ADXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 10-2009 | 10-2008 | 10-2007 | 12-2006 | 10-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 929 | -5,416 | -2,455 | N/A | -6,198 |
| Depreciation Amortization | 297 | 197 | 264 | N/A | 144 |
| Accounts payable and accrued liabilities | 1,422 | 212 | 99 | N/A | 158 |
| Other Working Capital | 1,315 | 671 | -418 | N/A | 787 |
| Other Operating Activity | -5,997 | 184 | -1,725 | 0 | 3,313 |
| Operating Cash Flow | $-2,035 | $-4,153 | $-4,234 | $N/A | $-1,795 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -11 | -38 | N/A | -9 |
| Purchase Sale Intangibles | -309 | -201 | -358 | N/A | -250 |
| Other Investing Activity | -309 | -201 | -358 | 0 | -250 |
| Investing Cash Flow | $-309 | $-211 | $-396 | $N/A | $-259 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 3,260 | 475 | 600 | N/A | N/A |
| Debt Issued | N/A | N/A | -2,040 | N/A | 3,000 |
| Common Stock Issued | N/A | -78 | 8,043 | N/A | N/A |
| Common Stock Repurchased | N/A | N/A | -600 | N/A | N/A |
| Other Financing Activity | -316 | -15 | -92 | 0 | -260 |
| Financing Cash Flow | $2,944 | $382 | $5,911 | $N/A | $2,740 |
| Beginning Cash Position | 60 | 4,042 | 2,761 | N/A | 2,075 |
| End Cash Position | 660 | 60 | 4,042 | N/A | 2,761 |
| Net Cash Flow | $600 | $-3,982 | $1,281 | $N/A | $686 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,035 | -4,153 | -4,234 | N/A | -1,795 |
| Capital Expenditure | N/A | -11 | -38 | N/A | -9 |
| Free Cash Flow | -2,035 | -4,164 | -4,272 | 0 | -1,804 |